National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Carfilzomib (Kyprolis®) in combination with lenalidomide and dexamethasone (CAR+LEN+DEX)

Kyprolis® (in combination with lenalidomide and dexamethasone) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Rapid Review

Commenced Completed Outcome
07/12/2015 06/01/2016 Full Pharmacoeconomic Evaluation Recommended


Pharmacoeconomic Evaluation

Commenced Completed Outcome
24/03/2016  19/10/2016 Reimbursement Not Recommended



The HSE has approved reimbursement following confidential price negotiations September 2018